Louise J Barber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2043232/publications.pdf Version: 2024-02-01



LOUISELRADRED

#	Article	IF	CITATIONS
1	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. Journal of the National Cancer Institute, 2021, 113, 88-98.	6.3	15
2	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. Nature Ecology and Evolution, 2021, 5, 1024-1032.	7.8	16
3	Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. Cancers, 2020, 12, 3736.	3.7	6
4	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nature Communications, 2020, 11, 139.	12.8	44
5	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell, 2019, 36, 35-50.e9.	16.8	179
6	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. Cancers, 2019, 11, 736.	3.7	15
7	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
8	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
9	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clinical Chemistry, 2018, 64, 1626-1635.	3.2	46
10	Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. Trends in Cancer, 2016, 2, 49-63.	7.4	222
11	Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Current Opinion in Genetics and Development, 2015, 30, 1-6.	3.3	57
12	The genomic landscape of oesophagogastric junctional adenocarcinoma. Journal of Pathology, 2013, 231, 301-310.	4.5	42
13	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. Clinical Cancer Research, 2013, 19, 5485-5493.	7.0	126
14	Secondary mutations in <i><scp>BRCA2</scp></i> associated with clinical resistance to a <scp>PARP</scp> inhibitor. Journal of Pathology, 2013, 229, 422-429.	4.5	287
15	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Annals of Oncology, 2013, 24, 1416-1418.	1.2	62
16	Comprehensive Genomic Analysis of a BRCA2 Deficient Human Pancreatic Cancer. PLoS ONE, 2011, 6, e21639.	2.5	17
17	C. elegans: A model of Fanconi anemia and ICL repair. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 668, 103-116.	1.0	34
18	Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene <i>MSH2</i> . EMBO Molecular Medicine, 2009, 1, 323-337.	6.9	154

LOUISE J BARBER

#	Article	IF	CITATIONS
19	The MRT-1 nuclease is required for DNA crosslink repair and telomerase activity in vivo in Caenorhabditis elegans. EMBO Journal, 2009, 28, 3549-3563.	7.8	50
20	Human SNM1A suppresses the DNA repair defects of yeast pso2 mutants. DNA Repair, 2008, 7, 230-238.	2.8	51
21	RTEL1 Maintains Genomic Stability by Suppressing Homologous Recombination. Cell, 2008, 135, 261-271.	28.9	315
22	DOG-1 Is the <i>Caenorhabditis elegans</i> BRIP1/FANCJ Homologue and Functions in Interstrand Cross-Link Repair. Molecular and Cellular Biology, 2008, 28, 1470-1479.	2.3	99
23	FANCJ Is a Structure-specific DNA Helicase Associated with the Maintenance of Genomic G/C Tracts. Journal of Biological Chemistry, 2008, 283, 36132-36139.	3.4	207
24	Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells. Cancer Research, 2007, 67, 8536-8543.	0.9	105
25	A Critical Role for the Ubiquitin-Conjugating Enzyme Ubc13 in Initiating Homologous Recombination. Molecular Cell, 2007, 25, 663-675.	9.7	210
26	HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nature Cell Biology, 2007, 9, 391-401.	10.3	111
27	Replication blocking lesions present a unique substrate for homologous recombination. EMBO Journal, 2007, 26, 3384-3396.	7.8	77
28	C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair. DNA Repair, 2006, 5, 1398-1406.	2.8	60
29	BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg?. DNA Repair, 2006, 5, 1499-1504.	2.8	15
30	DNA Interstrand Cross-Link Repair in the Saccharomyces cerevisiae Cell Cycle: Overlapping Roles for PSO2 (SNM1) with MutS Factors and EXO1 during S Phase. Molecular and Cellular Biology, 2005, 25, 2297-2309.	2.3	68
31	<i>Schizosaccharomyces pombe</i> Checkpoint Response to DNA Interstrand Cross-Links. Molecular and Cellular Biology, 2003, 23, 4728-4737.	2.3	33